Letters to the Editor
Use of Serum Markers in Myocardial Infarction
Am Fam Physician. 1998 Jan 15;57(2):226-229.
to the editor: The article by Dr. Chesebro1 provides useful and timely information regarding the often difficult diagnosis of myocardial infarction. Two points should be made regarding the use of cardiac troponin I (c-TnI) in this setting. First, rapid assays are available for c-TnI; they are currently in use at our institution. The turn-around time for c-TnI is equivalent to that of MB isoenzyme of creatine kinase (CK-MB) assays. Second, elevated c-TnI levels do not seem to be found in patients with renal failure (as Dr. Chesebro correctly points out), unlike CK-MB and cardiac troponin T, though the data to support this conclusion is lacking. We have found that c-TnI is a more accurate predictor of myocardial injury than CK-MB assays in patients with renal failure [Martin GS. February 1997. Unpublished data.], and that non-specific elevations of c-TnI do not seem to occur. Moreover, our data for patients with renal failure support Antman's conclusion2 about the population in general—that elevated c-TnI levels are associated with increased short-term mortality. With rapid c-TnI assays available, immediate decisions can be made regarding diagnosis of chest pain as well as stratifying patient risk. Cardiac troponin I and CK-MB complement each other because of their respective kinetics (rising in tandem, with CK-MB falling within 36 hours and c-TnI remaining positive for four to 10 days). As c-TnI assays become more widely available, evaluation of patients with suspected myocardial injury should become both simpler and more precise.
1. Chesebro MJ. Using serum markers in the early diagnosis of myocardial infarction. Am Fam Physician. 1997;55:2667–74.
2. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342–9.
in reply: I appreciate Dr. Martin's letter, as well as correspondence from Spectral Diagnostics, Inc., regarding their product, the Cardiac STATus Troponin I test kit, which uses seven to eight drops of whole blood, serum or plasma and gives results within 15 minutes. The improved predictive values, both positive and negative, of using c-TnI can improve our diagnostic capabilities when symptoms suggest acute myocardial infarction, and this improved capability can save lives through early intervention. Unfortunately, we are not readily discarding the older, less specific tests as the newer, more specific types become available. We may be creating more confusion by keeping the older tests (such as creatine phosphokinase [CPK] and CPK-MB), and combining them with myoglobin, troponin T and troponin I than if we relied on one or two with better positive and negative predictive values.
Send letters to firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions